<?xml version="1.0" encoding="UTF-8"?>
<p id="p0175">Modelling by the Centre for Disease Analysis has estimated the timeframe to break even with national investment in hepatitis B elimination, beyond which investment becomes cost saving (
 <xref rid="bib39" ref-type="bibr">39</xref>). For example, investment in hepatitis B elimination is estimated to provide cost savings in the Philippines by 2024 and in Vietnam by 2027. By 2035, for every dollar spent on hepatitis B elimination activities there would be an estimated return of US$2.23 in the Philippines and US$1.70 in Vietnam (
 <xref rid="bib39" ref-type="bibr">39</xref>).
</p>
